nach oben

Erschienen in:

06.11.2019 | Maternal-Fetal Medicine

The impact of neuropsychiatric disease on fetal growth: a case–control study

verfasst von: Lara Südekum, Anke Redlich, Anja Radusch, Sven Seeger, Siegfried Kropf, Ligang Zhou, Serban-Dan Costa, Gerhard Jorch, Anke Rissmann

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the impact of depression, epilepsy and drug abuse during pregnancy on delivery and fetal outcome. Due to the worldwide increasing prevalence of neurological and psychiatric diseases and drug abuse, the number of affected pregnant women is increasing.

Methods

A large-scale retrospective case–control analysis of pregnancies affected by depression, epilepsy or drug abuse with and without medication was conducted in two German perinatal centres between 2013 and 2017. The case group consisted of 706 pregnant women who had a diagnosis of depression, epilepsy or drug abuse vs. 12,574 pregnant women without neuropsychiatric diagnosis (control group). The analysis included the rate of intrauterine growth restriction, birth weight and length, neonatal head circumference.

Results

Significant differences in the subgroups were found in the parameters intrauterine growth restriction, birth weight, length and head circumference. Women with epilepsy were affected less often than women with depression and substance abuse. Major differences were found in the group of women with substance abuse. Negative associations were found within the non-pharmacologically managed disease group itself compared to women exposed to medication.

Conclusion

The present results demonstrated a negative association between maternal neurological or psychiatric disease and pregnancy outcome in the examined parameters. However, the non-pharmacologically treated maternal disease was identified as a risk factor itself.

Yang J, Kang C, Li J et al (2017) A three-decade repeated cross-sectional survey on mental health of the Chinese Jino minority. Aust N Z J Psychiatry 51(11):1134–1141. https://doi.org/10.1177/0004867416682599 CrossRefPubMed

Yin H, Xu G, Tian H et al (2017) The prevalence, age-of-onset and the correlates of DSM-IV psychiatric disorders in the Tianjin Mental Health Survey (TJMHS). Psychol Med. https://doi.org/10.1017/S0033291717001878 CrossRefPubMed

Hammond I, Eastman AL, Leventhal JM et al. (2017) Maternal Mental Health Disorders and Reports to Child Protective Services: A Birth Cohort Study. Int J Environ Res Public Health 14(11). 10.3390/ijerph14111320

Eastwood J, Ogbo FA, Hendry A et al (2017) The impact of antenatal depression on perinatal outcomes in Australian women. PLoS ONE 12(1):e0169907. https://doi.org/10.1371/journal.pone.0169907 CrossRefPubMedPubMedCentral

Ferreira CR, Orsini MC, Vieira CR et al (2015) Prevalence of anxiety symptoms and depression in the third gestational trimester. Arch Gynecol Obstet 291(5):999–1003. https://doi.org/10.1007/s00404-014-3508-x CrossRefPubMed

McHugh RK, Wigderson S, Greenfield SF (2014) Epidemiology of substance use in reproductive-age women. Obstet Gynecol Clin North Am 41(2):177–189. https://doi.org/10.1016/j.ogc.2014.02.001 CrossRefPubMedPubMedCentral

Maeda A, Bateman BT, Clancy CR et al (2014) Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology 121(6):1158–1165. https://doi.org/10.1097/ALN.0000000000000472 CrossRefPubMed

Kamyar M, Varner M (2013) Epilepsy in pregnancy. Clin Obstet Gynecol 56(2):330–341. https://doi.org/10.1097/GRF.0b013e31828f2436 CrossRefPubMed

Grunwald L, Jorch G, Kropf S et al (2016) The meaning of neurological and psychiatric disease and addiction for pregnancy outcome: a case-control study of the birth cohort 2010–2012. Z Geburtshilfe Neonatol 220(3):116–123. https://doi.org/10.1055/s-0042-101870 CrossRefPubMed

10.

Arora A, Patil A (2019) Time to take stock of Indian regulatory guidelines regarding drug use in pregnancy and lactation. Indian J Pharmacol 51(2):126–127. https://doi.org/10.4103/ijp.IJP_647_18 CrossRefPubMedPubMedCentral

11.

Boden R, Lundgren M, Brandt L et al. (2012) Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ 345(nov07 6):e7085. 10.1136/bmj.e7085

12.

Campbell E, Kennedy F, Russell A et al (2014) Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 85(9):1029–1034. https://doi.org/10.1136/jnnp-2013-306318 CrossRefPubMed

13.

Rapcencu AE, Lindhout D, Bulk S (2012) Frequently asked questions on epilepsy, pregnancy and lactation: a EURAP-NL report. Seizure 21(8):606–609. https://doi.org/10.1016/j.seizure.2012.06.011 CrossRefPubMed

14.

Schaefer C, Oppermann M, Wacker E et al (2012) Drug safety in pregnancy—the Embryotox project (Arzneimitteltherapiesicherheit in der Schwangerschaft—das Embryotox-Projekt). Z Evid Fortbild Qual Gesundhwes 106(10):723–728. https://doi.org/10.1016/j.zefq.2012.11.012 CrossRefPubMed

15.

Farmen AH, Grundt J, Tomson T et al (2015) Intrauterine growth retardation in foetuses of women with epilepsy. Seizure. https://doi.org/10.1016/j.seizure.2015.02.026 CrossRefPubMed

16.

Bonari L, Pinto N, Ahn E et al (2004) Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49(11):726–735CrossRefPubMed

17.

Wisner KL, Sit DKY, Hanusa BH et al (2009) Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 166(5):557–566. https://doi.org/10.1176/appi.ajp.2008.08081170 CrossRefPubMedPubMedCentral

18.

Tettenborn B (2006) Management of epilepsy in women of childbearing age: practical recommendations. CNS Drugs 20(5):373–387CrossRefPubMed

19.

Baer RJ, Chambers CD, Bandoli G et al (2016) Risk of preterm birth by subtype among Medi-Cal participants with mental illness. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2016.06.017 CrossRefPubMedPubMedCentral

20.

Bakhiet SFA, Essa YAS, Dwieb AMM et al (2017) Correlations between intelligence, head circumference and height: evidence from two samples in Saudi Arabia. J Biosoc Sci 49(2):276–280. https://doi.org/10.1017/S0021932016000249 CrossRefPubMed

21.

Neubauer V, Fuchs T, Griesmaier E et al (2016) Poor postdischarge head growth is related to a 10% lower intelligence quotient in very preterm infants at the chronological age of five years. Acta Paediatr 105(5):501–507. https://doi.org/10.1111/apa.13336 CrossRefPubMed

22.

DIMDI (2016) DIMDI-ICD-10-GM Version 2017. https://www.dimdi.de/static/de/klassifikationen/icd/icd-10-gm/kode-suche/htmlgm2017/. Accessed 04 Sep 2019

23.

Andersson L, Sundström-Poromaa I, Bixo M et al (2003) Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 189(1):148–154CrossRefPubMed

24.

Lee AM, Lam SK, Lau SM, Marie S et al (2007) Prevalence, course, and risk factors for antenatal anxiety and depression. Obstet Gynecol 110(5):1102–1112. https://doi.org/10.1097/01.AOG.0000287065.59491.70 CrossRefPubMed

25.

Verbeek T, Arjadi R, Vendrik JJ et al (2015) Anxiety and depression during pregnancy in Central America: a cross-sectional study among pregnant women in the developing country Nicaragua. BMC Psychiatry 15(1):292. https://doi.org/10.1186/s12888-015-0671-y CrossRefPubMedPubMedCentral

26.

Andrade SE, Raebel MA, Brown J et al (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198(2):194.e1–5. https://doi.org/10.1016/j.ajog.2007.07.036 CrossRef

27.

Ververs T, Kaasenbrood H, Visser G et al (2006) Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62(10):863–870. https://doi.org/10.1007/s00228-006-0177-0 CrossRefPubMed

28.

Charlton RA, Jordan S, Pierini A et al (2015) Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG 122(7):1010–1020. https://doi.org/10.1111/1471-0528.13143 CrossRefPubMed

29.

Artama M, Gissler M, Malm H et al (2013) Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. Drug Saf 36(5):359–369. https://doi.org/10.1007/s40264-013-0052-8 CrossRefPubMed

30.

Oluwafemi OR, Njokanma FO, Disu EA et al (2013) Current pattern of Ponderal Indices of term small-for-gestational age in a population of Nigerian babies. BMC Pediatr 13:110. https://doi.org/10.1186/1471-2431-13-110 CrossRefPubMedPubMedCentral

31.

Garite TJ, Clark R, Thorp JA (2004) Intrauterine growth restriction increases morbidity and mortality among premature neonates. Am J Obstet Gynecol 191(2):481–487. https://doi.org/10.1016/j.ajog.2004.01.036 CrossRefPubMed

32.

Sharma D, Shastri S, Sharma P (2016) Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr 10:67–83. https://doi.org/10.4137/CMPed.S40070 CrossRefPubMedPubMedCentral

33.

Guellec I, Lapillonne A, Renolleau S et al (2011) Neurologic outcomes at school age in very preterm infants born with severe or mild growth restriction. Pediatrics 127(4):e883–e891. https://doi.org/10.1542/peds.2010-2442 CrossRefPubMed

34.

Morsing E, Asard M, Ley D et al (2011) Cognitive function after intrauterine growth restriction and very preterm birth. Pediatrics 127(4):e874–e882. https://doi.org/10.1542/peds.2010-1821 CrossRefPubMed

35.

Saeed A, Raana T, Saeed AM et al (2016) Effect of antenatal depression on maternal dietary intake and neonatal outcome: a prospective cohort. Nutr J 15(1):64. https://doi.org/10.1186/s12937-016-0184-7 CrossRefPubMedPubMedCentral

36.

Bansil P, Kuklina EV, Meikle SF et al (2010) Maternal and fetal outcomes among women with depression. J Womens Health (Larchmt) 19(2):329–334. https://doi.org/10.1089/jwh.2009.1387 CrossRef

37.

Hompoth EA, Pető Z, Fűrészné Balogh V et al. (2019) Associations between depression symptoms, psychological intervention and perinatal complications. J Clin Psychol Med Settings. https://doi.org/10.1007/s10880-019-09632-4

38.

Ciesielski TH, Marsit CJ, Williams SM (2015) Maternal psychiatric disease and epigenetic evidence suggest a common biology for poor fetal growth. BMC Pregnancy Childbirth 15:192. https://doi.org/10.1186/s12884-015-0627-8 CrossRefPubMedPubMedCentral

39.

Chen D, Hou L, Duan X et al (2017) Effect of epilepsy in pregnancy on fetal growth restriction: a systematic review and meta-analysis. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-017-4404-y CrossRefPubMed

40.

Keegan J, Parva M, Finnegan M et al (2010) Addiction in pregnancy. J Addict Dis 29(2):175–191. https://doi.org/10.1080/10550881003684723 CrossRefPubMed

41.

Nobles CJ, Grantz KL, Liu D et al (2019) Ambient air pollution and fetal growth restriction: physician diagnosis of fetal growth restriction versus population-based small-for-gestational age. Sci Total Environ 650(Pt 2):2641–2647. https://doi.org/10.1016/j.scitotenv.2018.09.362 CrossRefPubMed

42.

Kandall SR, Albin S, Lowinson J et al (1976) Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 58(5):681–685PubMed

43.

Norgaard M, Nielsson MS, Heide-Jorgensen U (2015) Birth and Neonatal Outcomes Following Opioid Use in Pregnancy: A Danish Population-Based Study. Subst Abuse 9(Suppl 2):5–11. https://doi.org/10.4137/SART.S23547 CrossRefPubMedPubMedCentral

44.

Bier JB, Finger AS, Bier BA et al (2015) Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine. J Perinatol 35(8):656–659. https://doi.org/10.1038/jp.2015.22 CrossRefPubMed

45.

Towers CV, Hyatt BW, Visconti KC et al (2019) Neonatal head circumference in newborns with neonatal abstinence syndrome. Pediatrics 143(1):1. https://doi.org/10.1542/peds.2018-0541 CrossRef

46.

de Castro A, Jones HE, Johnson RE et al (2011) Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. Clin Chem 57(3):449–458. https://doi.org/10.1373/clinchem.2010.154864 CrossRefPubMedPubMedCentral

47.

Hasanjanzadeh P, Faramarzi M (2017) Relationship between maternal general and specific-pregnancy stress, anxiety, and depression symptoms and pregnancy outcome. J Clin Diagn Res 11(4):4–7. https://doi.org/10.7860/JCDR/2017/24352.9616 CrossRef

48.

Huang H, Coleman S, Bridge JA et al (2014) A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry 36(1):13–18. https://doi.org/10.1016/j.genhosppsych.2013.08.002 CrossRefPubMed

49.

Lewis AJ, Galbally M, Opie G et al (2010) Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry 44(5):482–487. https://doi.org/10.3109/00048670903559593 CrossRefPubMed

50.

Veiby G, Daltveit AK, Engelsen BA et al (2009) Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 50(9):2130–2139. https://doi.org/10.1111/j.1528-1167.2009.02147.x CrossRefPubMed

51.

Hernández-Díaz S, McElrath TF, Pennell PB et al (2017) Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol 82(3):457–465. https://doi.org/10.1002/ana.25031 CrossRefPubMed

52.

Liu AJW, Jones MP, Murray H et al (2010) Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol 50(3):253–258. https://doi.org/10.1111/j.1479-828X.2010.01168.x CrossRefPubMed

Titel: The impact of neuropsychiatric disease on fetal growth: a case–control study
verfasst von: Lara Südekum
Anke Redlich
Anja Radusch
Sven Seeger
Siegfried Kropf
Ligang Zhou
Serban-Dan Costa
Gerhard Jorch
Anke Rissmann
Publikationsdatum: 06.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 6/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-019-05361-z

Analysis of big data for prediction of provider-initiated preterm birth and spontaneous premature deliveries and ranking the predictive features

Maternal-Fetal Medicine

Serum zonulin level is not elevated in patients with polycystic ovary syndrome without metabolic syndrome

Gynecologic Endocrinology and Reproductive Medicine

Identification and characterization of uterine micro-peristalsis in women undergoing in vitro fertilization and embryo transfer via dynamic ultrasound features

Gynecologic Endocrinology and Reproductive Medicine

Tissue biomechanical behavior should be considered in the risk assessment of perineal trauma at childbirth

Guidelines and Position Statements

Overweight and obesity do not determine worst prognosis in endometrioid endometrial carcinoma

Gynecologic Oncology

Puerperal mastitis in the past decade: results of a single institution analysis

General Gynecology

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

10.01.2025
Mammakarzinom
Nachrichten

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

10.01.2025
Antiemetische Therapie
Nachrichten

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

The impact of neuropsychiatric disease on fetal growth: a case–control study